Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Zuyi Ma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8517-7600; OpenAlex author ID A5021361625. Sources: OpenAlex.

Their work

Papers
18 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
15
Papers, trials and grants by year

2020: 4 papers · 2021: 6 papers · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 18

  1. ATP-binding cassette subfamily A member 5 suppresses pancreatic ductal adenocarcinoma progression and chemoresistance by promoting β-catenin ubiquitin-dependen… First author DOI 10.1016/j.drup.2026.101381↗
  2. Nuclear magnetic resonance-based metabolomics and risk of pancreatic cancer: a prospective analysis in the UK Biobank. Co-author DOI 10.1007/s00535-025-02237-9↗
  3. Associations between triglyceride-glucose related indices and the risk of incident pancreatic cancer: a large-scale prospective cohort study in the UK Biobank. Co-author DOI 10.1186/s12885-025-13718-8↗
  4. LINC00909 up-regulates pluripotency factors and promotes cancer stemness and metastasis in pancreatic ductal adenocarcinoma by targeting SMAD4. First author DOI 10.1186/s13062-024-00463-4↗
  5. A hierarchical prognostic model for Co-diabetes pancreatic adenocarcinoma. Co-author DOI 10.1016/j.heliyon.2023.e21642↗
  6. Identification by genetic algorithm optimized back propagation artificial neural network and validation of a four-gene signature for diagnosis and prognosis of… First author DOI 10.1016/j.heliyon.2022.e11321↗
  7. Identification of MBOAT2 as an Unfavorable Biomarker Correlated with KRAS Activation and Reduced CD8+ T-Cell Infiltration in Pancreatic Cancer. Co-author DOI 10.1155/2022/4269733↗
  8. ZMAT1 acts as a tumor suppressor in pancreatic ductal adenocarcinoma by inducing SIRT3/p53 signaling pathway. Co-author DOI 10.1186/s13046-022-02310-8↗
  9. Prognostic values and immune suppression of the S100A family in pancreatic cancer. Co-author DOI 10.1111/jcmm.16343↗
  10. Identification of Prognostic and Therapeutic Biomarkers among FAM83 Family Members for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2021/6682697↗
  11. Development of a KRAS-Associated Metabolic Risk Model for Prognostic Prediction in Pancreatic Cancer. Co-author DOI 10.1155/2021/9949272↗
  12. Prognostic Nomogram for Patients With Pancreatic Ductal Adenocarcinoma of Pancreatic Head After Pancreaticoduodenectomy. Co-author DOI 10.1177/11795549211024149↗
  13. CMTM3 Overexpression Predicts Poor Survival and Promotes Proliferation and Migration in Pancreatic Cancer. First author DOI 10.7150/jca.57082↗
  14. Prognostic stratification based on a novel nomogram for left-sided pancreatic adenocarcinoma after surgical resection: a multi-center study. Co-author PMID 34249426↗
  15. Establishment of a 7-miRNA-Based Risk Score System for Predicting Prognosis of Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000001542↗
  16. Characterization of the prognostic and oncologic values of ITGB superfamily members in pancreatic cancer. Co-author DOI 10.1111/jcmm.15990↗
  17. A four prognosis-associated lncRNAs (PALnc) based risk score system reflects immune cell infiltration and predicts patient survival in pancreatic cancer. Co-author DOI 10.1186/s12935-020-01588-y↗
  18. B3GNT3 overexpression promotes tumor progression and inhibits infiltration of CD8+ T cells in pancreatic cancer. Co-author DOI 10.18632/aging.202255↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chuanzhao Zhang · 17 shared papers, 2020–2025 · strength 2.50
  2. Baohua Hou · 17 shared papers, 2020–2025 · strength 2.50
  3. Shanzhou Huang · 16 shared papers, 2020–2025 · strength 2.38
  4. Hongkai Zhuang · 14 shared papers, 2020–2024 · strength 1.82
  5. Zixuan Zhou · 14 shared papers, 2020–2024 · strength 1.82
  6. Zhenchong Li · 12 shared papers, 2020–2026 · strength 1.75
  7. Qi Zhou · 6 shared papers, 2021–2026 · strength 1.11
  8. Zelong Wu · 4 shared papers, 2023–2025 · strength 0.86
  9. Yuanfeng Gong · 5 shared papers, 2020–2021 · strength 0.60
  10. Shujie Wang · 4 shared papers, 2021–2023 · strength 0.58
  11. Yiping Zou · 3 shared papers, 2021 · strength 0.34
  12. Bowen Huang · 3 shared papers, 2021 · strength 0.34
  13. Bo Chen · 2 shared papers, 2021 · strength 0.25
  14. Shanzhou Huang · 1 shared paper, 2026 · strength 0.24
  15. Junchao Guo · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.